All In Biotech

Drug Trial Radar · NCT02101788

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

260

Actual

Start

Apr 11, 2014

Primary completion

Apr 4, 2019

Study completion Oct 27, 2025

Sponsor

Sponsor type
NIH
Collaborators
NRG Oncology
First posted
Apr 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back (recurrent), become worse (progressive), or spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective than standard therapy in treating patients with ovarian or peritoneal cavity cancer.

Conditions

  • Borderline Ovarian Serous Tumor
  • Micropapillary Serous Carcinoma
  • Ovarian Serous Adenocarcinoma
  • Primary Peritoneal Serous Adenocarcinoma
  • Recurrent Ovarian Low Grade Serous Adenocarcinoma
  • Recurrent Primary Peritoneal Serous Adenocarcinoma

Interventions

  • LetrozoleDrug

    Given PO

  • PaclitaxelDrug

    Given IV

  • Pegylated Liposomal Doxorubicin HydrochlorideDrug

    Given IV

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

  • Tamoxifen CitrateDrug

    Given PO

  • TopotecanDrug

    Given IV

  • Trametinib Dimethyl SulfoxideDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B

Locations

501 sites in 2 countries. Site status is shown where the registry gives one.

  • Tennessee Valley Gynecologic Oncology

    Huntsville, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • Community Cancer Institute

    Clovis, California

  • University Oncology Associates

    Clovis, California

  • Sutter Davis Hospital

    Davis, California

  • Palo Alto Medical Foundation-Fremont

    Fremont, California

  • Memorial Medical Center

    Modesto, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California

  • Sutter Cancer Research Consortium

    Novato, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • Sutter Cancer Centers Radiation Oncology Services-Roseville

    Roseville, California

  • Sutter Roseville Medical Center

    Roseville, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

  • Stanford Cancer Center South Bay

    San Jose, California

  • Palo Alto Medical Foundation-Santa Cruz

    Santa Cruz, California

  • Sutter Pacific Medical Foundation

    Santa Rosa, California

  • Palo Alto Medical Foundation-Sunnyvale

    Sunnyvale, California

  • Sutter Solano Medical Center/Cancer Center

    Vallejo, California

Showing 40 of 501 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.